With advanced IOL design and modern surgical technique, an exact refractive result following cataract surgery with implantation of an IOL is a reasonable expectation. Rayner Sulcoflex® Pseudophakic Supplementary IOLs are designed to correct any post-surgical or residual ametropia, without the trauma, or increased surgical risk, of an IOL exchange.
Moreover, unlike with conventional “piggy-back” IOL implantations, the unique design of Rayner Sulcoflex® Pseudophakic Supplementary IOLs ensures that the potential for contact between the two implants is minimised. This reduces the likelihood of induced refractive error and optical aberrations due to optic surface distortion at the area of contact between the IOLs.
Rayner Sulcoflex® Pseudophakic Supplementary IOLs are manufactured from Rayner’s proprietary hydrophilic acrylic co-polymer, Rayacryl®, which is noted for its exceptional uveal biocompatibility – a factor so important in those IOLs specifically intended for ciliary sulcus fixation. Rayacryl® is also noted for its superb optical clarity, with no vacuoles or glistenings. These factors, coupled with a remarkably low silicone oil adherence and excellent handling characteristics, means that Rayacryl® represents the ideal in IOL biomaterials.
The large optic diameter of Rayner Sulcoflex® Pseudophakic Supplementary IOLs ensures quality of vision with reduced risk of optic-iris capture and the round optic edge contributes to low rates of dysphotopsia.
The large diameter “undulating” haptics ensure IOL centration and rotational stability and the haptic angulation ensures uveal clearance, thereby avoiding pigment dispersion, and further reducing the risk of optic-iris capture.
The soft, round-edged haptic design ensures minimum tissue contact reaction.
Rayner Sulcoflex® Pseudophakic Supplementary IOLs are specifically indicated for:
Professor Michael Amon (Vienna, Austria) is the inventor of Sulcoflex® Pseudophakic Supplementary IOLs. Sulcoflex® patent pending.
